BELUMOSUDIL MESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for belumosudil mesylate and what is the scope of patent protection?
Belumosudil mesylate
is the generic ingredient in one branded drug marketed by Kadmon Pharms Llc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Belumosudil mesylate has forty-seven patent family members in twenty-seven countries.
One supplier is listed for this compound.
Summary for BELUMOSUDIL MESYLATE
International Patents: | 47 |
US Patents: | 5 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | BELUMOSUDIL MESYLATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BELUMOSUDIL MESYLATE
Generic Entry Date for BELUMOSUDIL MESYLATE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for BELUMOSUDIL MESYLATE
International Patents for BELUMOSUDIL MESYLATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Singapore | 155163 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ⤷ Try a Trial |
Serbia | 63503 | INHIBITORI RHO KINAZE (RHO KINASE INHIBITORS) | ⤷ Try a Trial |
South Korea | 20080081122 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2014055996 | ⤷ Try a Trial | |
Japan | 2019034949 | RHOキナーゼ阻害剤 (RHO KINASE INHIBITOR) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |